ALKERMES PLC (ALKS) Stock Fundamental Analysis

NASDAQ:ALKS • IE00B56GVS15

30.1 USD
-0.63 (-2.05%)
At close: Feb 27, 2026
30.1 USD
0 (0%)
Pre-Market: 3/2/2026, 6:01:55 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

ALKS gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. ALKS has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. ALKS is not valued too expensively and it also shows a decent growth rate. These ratings could make ALKS a good candidate for quality investing.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • ALKS had positive earnings in the past year.
  • In the past year ALKS had a positive cash flow from operations.
  • In multiple years ALKS reported negative net income over the last 5 years.
  • ALKS had a positive operating cash flow in each of the past 5 years.
ALKS Yearly Net Income VS EBIT VS OCF VS FCFALKS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

1.2 Ratios

  • ALKS has a better Return On Assets (9.72%) than 93.65% of its industry peers.
  • ALKS has a Return On Equity of 13.28%. This is amongst the best in the industry. ALKS outperforms 94.04% of its industry peers.
  • ALKS has a Return On Invested Capital of 10.90%. This is amongst the best in the industry. ALKS outperforms 94.42% of its industry peers.
  • ALKS had an Average Return On Invested Capital over the past 3 years of 18.21%. This is in line with the industry average of 17.87%.
  • The 3 year average ROIC (18.21%) for ALKS is well above the current ROIC(10.90%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 9.72%
ROE 13.28%
ROIC 10.9%
ROA(3y)14.74%
ROA(5y)6.76%
ROE(3y)22.64%
ROE(5y)9.68%
ROIC(3y)18.21%
ROIC(5y)N/A
ALKS Yearly ROA, ROE, ROICALKS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20

1.3 Margins

  • ALKS has a Profit Margin of 16.37%. This is amongst the best in the industry. ALKS outperforms 92.12% of its industry peers.
  • With an excellent Operating Margin value of 17.21%, ALKS belongs to the best of the industry, outperforming 93.27% of the companies in the same industry.
  • ALKS has a better Gross Margin (86.69%) than 88.85% of its industry peers.
  • ALKS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 17.21%
PM (TTM) 16.37%
GM 86.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.55%
GM growth 5Y0.92%
ALKS Yearly Profit, Operating, Gross MarginsALKS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ALKS is creating value.
  • ALKS has more shares outstanding than it did 1 year ago.
  • ALKS has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for ALKS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ALKS Yearly Shares OutstandingALKS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
ALKS Yearly Total Debt VS Total AssetsALKS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • An Altman-Z score of 5.65 indicates that ALKS is not in any danger for bankruptcy at the moment.
  • ALKS has a better Altman-Z score (5.65) than 73.65% of its industry peers.
  • There is no outstanding debt for ALKS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 5.65
ROIC/WACC1.39
WACC7.86%
ALKS Yearly LT Debt VS Equity VS FCFALKS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 3.55 indicates that ALKS has no problem at all paying its short term obligations.
  • ALKS has a Current ratio of 3.55. This is comparable to the rest of the industry: ALKS outperforms 41.73% of its industry peers.
  • ALKS has a Quick Ratio of 3.19. This indicates that ALKS is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 3.19, ALKS is not doing good in the industry: 60.58% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.55
Quick Ratio 3.19
ALKS Yearly Current Assets VS Current LiabilitesALKS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • ALKS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -34.90%.
  • The Earnings Per Share has been growing by 34.43% on average over the past years. This is a very strong growth
  • ALKS shows a decrease in Revenue. In the last year, the revenue decreased by -5.25%.
  • Measured over the past years, ALKS shows a small growth in Revenue. The Revenue has been growing by 7.28% on average per year.
EPS 1Y (TTM)-34.9%
EPS 3Y77.08%
EPS 5Y34.43%
EPS Q2Q%-56.19%
Revenue 1Y (TTM)-5.25%
Revenue growth 3Y9.9%
Revenue growth 5Y7.28%
Sales Q2Q%-10.57%

3.2 Future

  • The Earnings Per Share is expected to grow by 8.40% on average over the next years. This is quite good.
  • ALKS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.44% yearly.
EPS Next Y-20.69%
EPS Next 2Y-9.41%
EPS Next 3Y3.97%
EPS Next 5Y8.4%
Revenue Next Year23.02%
Revenue Next 2Y12.82%
Revenue Next 3Y10.55%
Revenue Next 5Y10.44%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ALKS Yearly Revenue VS EstimatesALKS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B
ALKS Yearly EPS VS EstimatesALKS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 15.93 indicates a correct valuation of ALKS.
  • Based on the Price/Earnings ratio, ALKS is valued cheaper than 95.19% of the companies in the same industry.
  • ALKS is valuated rather cheaply when we compare the Price/Earnings ratio to 27.07, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 20.10, the valuation of ALKS can be described as rather expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of ALKS indicates a rather cheap valuation: ALKS is cheaper than 93.08% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.05, ALKS is valued a bit cheaper.
Industry RankSector Rank
PE 15.93
Fwd PE 20.1
ALKS Price Earnings VS Forward Price EarningsALKS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ALKS indicates a rather cheap valuation: ALKS is cheaper than 95.00% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, ALKS is valued cheaper than 97.88% of the companies in the same industry.
Industry RankSector Rank
P/FCF 10.35
EV/EBITDA 14.88
ALKS Per share dataALKS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

  • The decent profitability rating of ALKS may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.46
EPS Next 2Y-9.41%
EPS Next 3Y3.97%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ALKS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALKERMES PLC

NASDAQ:ALKS (2/27/2026, 8:00:00 PM)

Premarket: 30.1 0 (0%)

30.1

-0.63 (-2.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)04-29
Inst Owners105.82%
Inst Owner Change2.02%
Ins Owners1.48%
Ins Owner Change6.38%
Market Cap4.97B
Revenue(TTM)1.48B
Net Income(TTM)241.66M
Analysts80.87
Price Target44.69 (48.47%)
Short Float %11.74%
Short Ratio10.15
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)48.47%
Min EPS beat(2)37.11%
Max EPS beat(2)59.84%
EPS beat(4)4
Avg EPS beat(4)45.33%
Min EPS beat(4)12.02%
Max EPS beat(4)72.36%
EPS beat(8)5
Avg EPS beat(8)22.16%
EPS beat(12)8
Avg EPS beat(12)29.21%
EPS beat(16)11
Avg EPS beat(16)142.72%
Revenue beat(2)1
Avg Revenue beat(2)3.62%
Min Revenue beat(2)-1.27%
Max Revenue beat(2)8.51%
Revenue beat(4)2
Avg Revenue beat(4)4.55%
Min Revenue beat(4)-1.27%
Max Revenue beat(4)12.13%
Revenue beat(8)3
Avg Revenue beat(8)2.68%
Revenue beat(12)6
Avg Revenue beat(12)3.44%
Revenue beat(16)9
Avg Revenue beat(16)2.77%
PT rev (1m)0.29%
PT rev (3m)0.57%
EPS NQ rev (1m)-1.13%
EPS NQ rev (3m)-3.14%
EPS NY rev (1m)-0.46%
EPS NY rev (3m)-0.83%
Revenue NQ rev (1m)0.49%
Revenue NQ rev (3m)0.87%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)0.2%
Valuation
Industry RankSector Rank
PE 15.93
Fwd PE 20.1
P/S 3.37
P/FCF 10.35
P/OCF 9.54
P/B 2.73
P/tB 2.86
EV/EBITDA 14.88
EPS(TTM)1.89
EY6.28%
EPS(NY)1.5
Fwd EY4.97%
FCF(TTM)2.91
FCFY9.66%
OCF(TTM)3.15
OCFY10.48%
SpS8.94
BVpS11.02
TBVpS10.51
PEG (NY)N/A
PEG (5Y)0.46
Graham Number21.65
Profitability
Industry RankSector Rank
ROA 9.72%
ROE 13.28%
ROCE 13.07%
ROIC 10.9%
ROICexc 15.63%
ROICexgc 16.66%
OM 17.21%
PM (TTM) 16.37%
GM 86.69%
FCFM 32.55%
ROA(3y)14.74%
ROA(5y)6.76%
ROE(3y)22.64%
ROE(5y)9.68%
ROIC(3y)18.21%
ROIC(5y)N/A
ROICexc(3y)43.15%
ROICexc(5y)N/A
ROICexgc(3y)50.12%
ROICexgc(5y)N/A
ROCE(3y)21.84%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.55%
GM growth 5Y0.92%
F-Score6
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 148.79%
Cap/Sales 2.74%
Interest Coverage 250
Cash Conversion 185.24%
Profit Quality 198.76%
Current Ratio 3.55
Quick Ratio 3.19
Altman-Z 5.65
F-Score6
WACC7.86%
ROIC/WACC1.39
Cap/Depr(3y)110.09%
Cap/Depr(5y)83%
Cap/Sales(3y)2.59%
Cap/Sales(5y)2.72%
Profit Quality(3y)136.19%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-34.9%
EPS 3Y77.08%
EPS 5Y34.43%
EPS Q2Q%-56.19%
EPS Next Y-20.69%
EPS Next 2Y-9.41%
EPS Next 3Y3.97%
EPS Next 5Y8.4%
Revenue 1Y (TTM)-5.25%
Revenue growth 3Y9.9%
Revenue growth 5Y7.28%
Sales Q2Q%-10.57%
Revenue Next Year23.02%
Revenue Next 2Y12.82%
Revenue Next 3Y10.55%
Revenue Next 5Y10.44%
EBIT growth 1Y-39.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.82%
EBIT Next 3Y28.61%
EBIT Next 5Y30.01%
FCF growth 1Y18.41%
FCF growth 3YN/A
FCF growth 5Y63.91%
OCF growth 1Y18.59%
OCF growth 3Y191.61%
OCF growth 5Y44.45%

ALKERMES PLC / ALKS FAQ

What is the fundamental rating for ALKS stock?

ChartMill assigns a fundamental rating of 6 / 10 to ALKS.


What is the valuation status of ALKERMES PLC (ALKS) stock?

ChartMill assigns a valuation rating of 6 / 10 to ALKERMES PLC (ALKS). This can be considered as Fairly Valued.


Can you provide the profitability details for ALKERMES PLC?

ALKERMES PLC (ALKS) has a profitability rating of 7 / 10.


Can you provide the expected EPS growth for ALKS stock?

The Earnings per Share (EPS) of ALKERMES PLC (ALKS) is expected to decline by -20.69% in the next year.